Summary
0.74 0.02(2.26%)07/01/2024
Seres Therapeutics Inc (MCRB)
Seres Therapeutics Inc (MCRB)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -0.22 | -3.51 | -31.44 | -3.27 | -47.13 | -84.89 | -74.91 | -98.56 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 0.74 | |
| Open | 0.76 | |
| High | 0.79 | |
| Low | 0.74 | |
| Volume | 1,635,138 | |
| Change | -0.00 | |
| Change % | -0.22 | |
| Avg Volume (20 Days) | 2,129,959 | |
| Volume/Avg Volume (20 Days) Ratio | 0.77 | |
| 52 Week Range | 0.54 - 5.29 | |
| Price vs 52 Week High | -86.01% | |
| Price vs 52 Week Low | 37.07% | |
| Range | -2.48 | |
| Gap Up/Down | -0.04 | |
Fundamentals | ||
| Market Capitalization (Mln) | 109 | |
| EBIDTA | -70,599,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | -0.1100 | |
| WallStreet Target Price | 6.20 | |
| Book Value | -0.3940 | |
| Earnings Per Share | -0.8900 | |
| EPS Estimate Current Quarter | -0.3400 | |
| EPS Estimate Next Quarter | -0.3100 | |
| EPS Estimate Current Year | -1.0500 | |
| EPS Estimate Next Year | -0.8300 | |
| Diluted EPS (TTM) | -0.8900 | |
| Revenues | ||
| Profit Marging | -0.6518 | |
| Operating Marging (TTM) | -0.6070 | |
| Return on asset (TTM) | -0.1574 | |
| Return on equity (TTM) | -5.3857 | |
| Revenue TTM | 126,847,000 | |
| Revenue per share TTM | 0.9530 | |
| Quarterly Revenue Growth (YOY) | -0.9340 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | -165,792,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 63.8391 | |
| Revenue Enterprise Value | 1.4632 | |
| EBITDA Enterprise Value | -1.9600 | |
| Shares | ||
| Shares Outstanding | 151,008,992 | |
| Shares Float | 119,551,350 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.20 | |
| Insider (%) | 5.66 | |
| Institutions (%) | 58.49 | |
06/07 16:00 EST - globenewswire.com
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass, June 07, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on June 5, 2024, the Compensation and Talent Committee of Seres' board of directors granted inducement equity grants covering an aggregate of 6,188 shares of its common stock to one new employee, consisting of stock options to purchase 4,125 shares of common stock and restricted stock units (“RSUs”) covering 2,063 shares of its common stock.
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass, June 07, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on June 5, 2024, the Compensation and Talent Committee of Seres' board of directors granted inducement equity grants covering an aggregate of 6,188 shares of its common stock to one new employee, consisting of stock options to purchase 4,125 shares of common stock and restricted stock units (“RSUs”) covering 2,063 shares of its common stock.
06/06 07:00 EST - prnewswire.com
Nestlé Health Science agrees to acquire global rights to VOWST®, product it launched in June 2023
Transaction ensures Nestlé Health Science will continue to commercialize the product BRIDGEWATER, N.J. , June 6, 2024 /PRNewswire/ -- Seres Therapeutics, Inc. (Nasdaq: MCRB), announced today that it has agreed to a non-binding memorandum of understanding with Nestlé Health Science in which Nestlé Health Science will acquire certain tangible and intangible assets associated with VOWST (fecal microbiota spores, live-brpk) capsules.
Nestlé Health Science agrees to acquire global rights to VOWST®, product it launched in June 2023
Transaction ensures Nestlé Health Science will continue to commercialize the product BRIDGEWATER, N.J. , June 6, 2024 /PRNewswire/ -- Seres Therapeutics, Inc. (Nasdaq: MCRB), announced today that it has agreed to a non-binding memorandum of understanding with Nestlé Health Science in which Nestlé Health Science will acquire certain tangible and intangible assets associated with VOWST (fecal microbiota spores, live-brpk) capsules.
06/06 06:30 EST - globenewswire.com
Seres Therapeutics Enters Into Memorandum of Understanding For Vowst™ Asset Sale to Nestlé Health Science
Seres anticipates capital infusions, including an upfront payment, enabling the Company to fully retire its debt and extend its cash runway into Q4 2025, pending deal closure and subject to performance under a transition services agreement
Seres Therapeutics Enters Into Memorandum of Understanding For Vowst™ Asset Sale to Nestlé Health Science
Seres anticipates capital infusions, including an upfront payment, enabling the Company to fully retire its debt and extend its cash runway into Q4 2025, pending deal closure and subject to performance under a transition services agreement
05/11 17:34 EST - seekingalpha.com
Seres Therapeutics, Inc. (MCRB) Q1 2024 Earnings Call Transcript
Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q1 2024 Results Conference Call May 8, 2024 8:30 AM ET Company Participants Carlo Tanzi - IR Eric Shaff - CEO Terri Young - Chief Commercial and Strategy Officer Lisa von Moltke - Chief Medical Officer Marella Thorell - CFO Matthew Henn - EVP, Chief Scientific Officer Conference Call Participants Ted Tenthoff - Piper Sandler John Newman - Canaccord Genuity Tess Romero - JPMorgan Jeff Jones - Oppenheimer Keay Nakae - Chardan Operator Thank you for standing by. My name is Alex, and I will be your conference operator today.
Seres Therapeutics, Inc. (MCRB) Q1 2024 Earnings Call Transcript
Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q1 2024 Results Conference Call May 8, 2024 8:30 AM ET Company Participants Carlo Tanzi - IR Eric Shaff - CEO Terri Young - Chief Commercial and Strategy Officer Lisa von Moltke - Chief Medical Officer Marella Thorell - CFO Matthew Henn - EVP, Chief Scientific Officer Conference Call Participants Ted Tenthoff - Piper Sandler John Newman - Canaccord Genuity Tess Romero - JPMorgan Jeff Jones - Oppenheimer Keay Nakae - Chardan Operator Thank you for standing by. My name is Alex, and I will be your conference operator today.
05/08 07:00 EST - businesswire.com
Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported first quarter 2024 financial results and provided business updates. "With a broad indication and compelling clinical profile to prevent the recurrence of Clostridioides difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI (rCDI), VOWST enables healthcare providers to fundamentally transform how they treat this life-threatening d.
Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported first quarter 2024 financial results and provided business updates. "With a broad indication and compelling clinical profile to prevent the recurrence of Clostridioides difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI (rCDI), VOWST enables healthcare providers to fundamentally transform how they treat this life-threatening d.
05/06 09:30 EST - businesswire.com
Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on May 8, 2024 at 8:30 a.m. ET to discuss first quarter 2024 financial results and provide business updates. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 5686561. To join the live webcast, please visit th.
Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on May 8, 2024 at 8:30 a.m. ET to discuss first quarter 2024 financial results and provide business updates. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 5686561. To join the live webcast, please visit th.
04/09 07:00 EST - businesswire.com
Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that enrollment is complete in the placebo-controlled Cohort 2 of its Phase 1b trial of SER-155 in patients who received Allogeneic Hematopoietic Stem Cell Transplantation (Allo HSCT). SER-155 is an orally administered, consortium of bacteria, cultivated from cell banks and designed to reduce the incidence and severity of enteric-derived infections and resulting.
Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that enrollment is complete in the placebo-controlled Cohort 2 of its Phase 1b trial of SER-155 in patients who received Allogeneic Hematopoietic Stem Cell Transplantation (Allo HSCT). SER-155 is an orally administered, consortium of bacteria, cultivated from cell banks and designed to reduce the incidence and severity of enteric-derived infections and resulting.
03/05 15:33 EST - seekingalpha.com
Seres Therapeutics, Inc. (MCRB) Q4 2023 Earnings Call Transcript
Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q4 2023 Earnings Call Transcript March 5, 2024 8:30 AM ET Company Participants Rob Windsor - IR Eric Shaff - CEO Terri Young - CCO & CSO Lisa von Moltke - CMO David Arkowitz - CFO Dave Ege - CTO Matthew Henn - Chief Scientific Officer Conference Call Participants Jeff Jones - Oppenheimer John Newman - Canaccord Tess Romero - JPMorgan Peyton Bohnsack - TD Cowen Chris Shibutani - Goldman Sachs Keay Nakae - Chardan Operator Ladies and gentlemen, good morning. My name is Abby, and will be your conference operator today.
Seres Therapeutics, Inc. (MCRB) Q4 2023 Earnings Call Transcript
Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q4 2023 Earnings Call Transcript March 5, 2024 8:30 AM ET Company Participants Rob Windsor - IR Eric Shaff - CEO Terri Young - CCO & CSO Lisa von Moltke - CMO David Arkowitz - CFO Dave Ege - CTO Matthew Henn - Chief Scientific Officer Conference Call Participants Jeff Jones - Oppenheimer John Newman - Canaccord Tess Romero - JPMorgan Peyton Bohnsack - TD Cowen Chris Shibutani - Goldman Sachs Keay Nakae - Chardan Operator Ladies and gentlemen, good morning. My name is Abby, and will be your conference operator today.
03/05 10:18 EST - investorplace.com
Gold Price Alert: Gold Spot Prices Just Hit a Record High Today
Investors in gold are excited on Tuesday as the spot price of the precious metal hit a recent high of $2,113.28 per ounce during a rally yesterday. The increasing price of gold is catching up to its current record high of $2,135.40 that was achieved in December 2023.
Gold Price Alert: Gold Spot Prices Just Hit a Record High Today
Investors in gold are excited on Tuesday as the spot price of the precious metal hit a recent high of $2,113.28 per ounce during a rally yesterday. The increasing price of gold is catching up to its current record high of $2,135.40 that was achieved in December 2023.
03/05 07:00 EST - businesswire.com
Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported fourth quarter and full year 2023 financial results and provided business updates. “2023 was an historic year for Seres as we launched our first-in-class oral microbiome therapeutic, VOWST, for recurrent CDI into commercialization with our collaborators at Nestlé Health Science,” said Eric Shaff, President and Chief Executive Officer of Seres. “We are proud of th.
Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported fourth quarter and full year 2023 financial results and provided business updates. “2023 was an historic year for Seres as we launched our first-in-class oral microbiome therapeutic, VOWST, for recurrent CDI into commercialization with our collaborators at Nestlé Health Science,” said Eric Shaff, President and Chief Executive Officer of Seres. “We are proud of th.
02/28 07:00 EST - businesswire.com
Seres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on March 5, 2024 at 8:30 a.m. ET to discuss fourth quarter and full year 2023 results and provide a general business update. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 4030622. To join the live webcast,.
Seres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on March 5, 2024 at 8:30 a.m. ET to discuss fourth quarter and full year 2023 results and provide a general business update. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 4030622. To join the live webcast,.
02/27 07:00 EST - businesswire.com
Seres Therapeutics to Participate in Cowen 44th Annual Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will participate in a panel discussion at the Cowen 44th Annual Health Care Conference on Wednesday, March 6, 2024 at 9:10 a.m. ET. An audio webcast of the panel discussion will be available under the “Investors and News” section of Seres' website. A replay of the presentation will bec.
Seres Therapeutics to Participate in Cowen 44th Annual Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will participate in a panel discussion at the Cowen 44th Annual Health Care Conference on Wednesday, March 6, 2024 at 9:10 a.m. ET. An audio webcast of the panel discussion will be available under the “Investors and News” section of Seres' website. A replay of the presentation will bec.
02/26 07:00 EST - businesswire.com
Seres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David Arkowitz
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that Marella Thorell will join as Executive Vice President and Chief Financial Officer (CFO), as of March 25th, following David Arkowitz's retirement. Mr. Arkowitz has served as CFO since June 2021 and will be available to assist in the transition. Ms. Thorell is a seasoned enterprise leader with deep life sciences and biotechnology industry experience in both p.
Seres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David Arkowitz
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that Marella Thorell will join as Executive Vice President and Chief Financial Officer (CFO), as of March 25th, following David Arkowitz's retirement. Mr. Arkowitz has served as CFO since June 2021 and will be available to assist in the transition. Ms. Thorell is a seasoned enterprise leader with deep life sciences and biotechnology industry experience in both p.
01/09 07:00 EST - businesswire.com
Seres Therapeutics Announces VOWST™ Commercial Launch Update and US FDA Fast Track Designation for SER-155
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced preliminary key VOWST (fecal microbiota spores, live-brpk) launch metrics and receipt of US FDA Fast Track Designation for SER-155 ahead of its presentation at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10th. VOWST, the first FDA approved orally administered microbiome therapeutic, received FDA approval in April of 2023 and is indica.
Seres Therapeutics Announces VOWST™ Commercial Launch Update and US FDA Fast Track Designation for SER-155
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced preliminary key VOWST (fecal microbiota spores, live-brpk) launch metrics and receipt of US FDA Fast Track Designation for SER-155 ahead of its presentation at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10th. VOWST, the first FDA approved orally administered microbiome therapeutic, received FDA approval in April of 2023 and is indica.
01/04 16:00 EST - businesswire.com
Seres Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres management will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 10, 2024, at 12:45 p.m. ET / 9:45 am PT. An audio webcast of the presentation will be available under the “Investors and News” section of Seres' website. A replay of the presentation will become available approximately one hour after.
Seres Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres management will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 10, 2024, at 12:45 p.m. ET / 9:45 am PT. An audio webcast of the presentation will be available under the “Investors and News” section of Seres' website. A replay of the presentation will become available approximately one hour after.
12/07 19:46 EST - businesswire.com
Seres Therapeutics Announces Presentation of Preliminary PK/PD and Safety Data for Investigational Microbiome Therapeutic SER-155 at ASH 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that preliminary clinical data from a currently enrolling Phase 1b study of SER-155 study in adult patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) will be presented at the 65th American Society of Hematology (ASH) Annual Meeting held from December 9-12, 2023, in San Diego, California, USA. SER-155 is an oral, cultivated live bacteria.
Seres Therapeutics Announces Presentation of Preliminary PK/PD and Safety Data for Investigational Microbiome Therapeutic SER-155 at ASH 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that preliminary clinical data from a currently enrolling Phase 1b study of SER-155 study in adult patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) will be presented at the 65th American Society of Hematology (ASH) Annual Meeting held from December 9-12, 2023, in San Diego, California, USA. SER-155 is an oral, cultivated live bacteria.